Answers are grounded in this paper and cite their sources.
In this population with high-risk anti-PLA2R+ PMN, felzartamab was tolerated and resulted in rapid partial and complete immunologic responses and partial improvements in proteinuria and serum albumin in some patients.
No takes yet. Share an insight, caveat, or question.
Rovin et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: